Asset Details
Do you wish to reserve the book?
CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients
Do you wish to request the book?
CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients
2017
Overview
The CXCR4 receptor and its ligand CXCL12 (also named stromal cell-derived factor 1, SDF1) have a critical role in chemotaxis and homing, key steps in cancer metastasis. Although myofibroblasts expressing CXCL12 are associated with the presence of axillary metastases in HER2 breast cancers (BC), the therapeutic interest of targeting CXCR4/CXCL12 axis in the different BC subtypes remains unclear. Here, we investigate this question by testing antitumor activity of CXCR4 inhibitors in patient-derived xenografts (PDX), which faithfully reproduce human tumor properties. We observed that two CXCR4 inhibitors, AMD3100 and TN14003, efficiently impair tumor growth and metastasis dissemination in both Herceptin-sensitive and Herceptin-resistant HER2 BC. Conversely, blocking CXCR4/CXCL12 pathway in triple-negative (TN) BC does not reduce tumor growth, and can even increase metastatic spread. Moreover, although CXCR4 inhibitors significantly reduce myofibroblast content in all BC subtypes, they decrease angiogenesis only in HER2 BC. Thus, our findings suggest that targeting CXCR4 could provide some therapeutic interest for HER2 BC patients, whereas it has no impact or could even be detrimental for TN BC patients.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Publishing Group [1987-....]
Subject
/ 13/51
/ 64/60
/ 82/80
/ Animals
/ Anti-HIV Agents - pharmacology
/ Biomarkers, Tumor - metabolism
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - metabolism
/ Breast Neoplasms - pathology
/ Cancer
/ Cell Proliferation - drug effects
/ Female
/ Gene Expression Regulation, Neoplastic - drug effects
/ Heterocyclic Compounds - pharmacology
/ Humans
/ Ligands
/ Lung Neoplasms - drug therapy
/ Medicine
/ Mice
/ Neovascularization, Pathologic - drug therapy
/ Oncology
/ Original
/ Receptor, ErbB-2 - metabolism
/ Receptors, CXCR4 - antagonists & inhibitors
/ Triple Negative Breast Neoplasms - drug therapy
/ Triple Negative Breast Neoplasms - metabolism
